Scinai Immunotherapeutics (SCNI) Profit After Tax (2014 - 2024)

Scinai Immunotherapeutics has disclosed Profit After Tax across 11 years of filings, most recently posting -$2.3 million for Q4 2024.

• Profit After Tax for Q4 2024 came in at -$2.3 million, up 2.88% year-over-year; the trailing twelve-month figure through Dec 2024 was $13.2 million (up 615.87% YoY), and the FY2025 annual result was -$11.0 million, down 328.54% from the prior year.
• Profit After Tax came in at -$2.3 million for Q4 2024 at Scinai Immunotherapeutics, down from $11.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $55.3 million in Q3 2020 to a low of -$14.1 million in Q4 2020.
• The 5-year median for Profit After Tax is -$2.3 million (2023), against an average of $2.0 million.
• Across the five-year window, Profit After Tax plunged 752.83% in 2020 and surged 78635.87% in 2023, its largest moves.
• Scinai Immunotherapeutics' Profit After Tax stood at -$14.1 million in 2020, then surged by 249.1% to $21.0 million in 2021, then sank by 124.34% to -$5.1 million in 2022, then surged by 54.46% to -$2.3 million in 2023, then climbed by 2.88% to -$2.3 million in 2024.
• The last three Profit After Tax figures came in at -$2.3 million (Q4 2024), $11.0 million (Q3 2024), and $2.3 million (Q2 2024), per Business Quant data.